Short Communication: Persistence of HIV After Allogeneic Bone Marrow Transplant in a Dually Infected Individual
| Autor: | Richard F. Ambinder, Christopher D. Gocke, Adam A. Capoferri, Laura R. Clark, Andrew D. Redd, Christine M. Durand |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
CD4-Positive T-Lymphocytes
0301 basic medicine Donor cell Immunology Human immunodeficiency virus (HIV) HIV Infections medicine.disease_cause Virus Persistence (computer science) 03 medical and health sciences 0302 clinical medicine Dual infection Virology Humans Medicine 030212 general & internal medicine Phylogeny Bone Marrow Transplantation business.industry Hematopoietic Stem Cell Transplantation Viral Load Antiretroviral therapy Reverse transcriptase 030104 developmental biology Infectious Diseases Anti-Retroviral Agents business Allogeneic bone marrow transplant |
| Zdroj: | AIDS Res Hum Retroviruses |
| ISSN: | 1931-8405 0889-2229 |
| DOI: | 10.1089/aid.2021.0047 |
| Popis: | Allogeneic bone marrow transplant (alloBMT) with continuous antiretroviral therapy alone has not been shown to completely eradicate HIV, possibly due to HIV persistence in rare residual host cells or infection of donor cells. Within a trial of alloBMT in individuals with hematological malignancies and HIV (ClinicalTrials.gov, NCT01836068), we measured HIV reservoirs longitudinally using a quantitative viral outgrowth assay. We sequenced the reverse transcriptase region of pol for replication-competent virus and performed maximum-likelihood phylogenetic reconstruction. Replacement of host cells was measured using short-tandem repeats. In one participant who had ≥99.5% donor cell replacement, HIV reservoirs declined from 2.2 infectious units per million to undetectable levels at post-alloBMT time points except for week 64. Sequence analysis revealed dual infection pre-alloBMT. Replication-competent virus isolated at week 64 post-alloBMT was identical to a pre-alloBMT variant. This report provides proof-of-concept that minor replication-competent HIV variants can persist at low levels despite ≥99.5% donor cell engraftment post-alloBMT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|